Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Zeitschrift für Gerontologie und Geriatrie 2/2019

23.02.2018 | Original contributions

Prevention of ovariectomy-induced osteoporosis in rats

Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate

verfasst von: Zhou-Shan Tao, Wan-Shu Zhou, Xing-Jing Wu, Xin Zhang, Lin Wang, Jia-Bing Xie, Zhu-Jun Xu, Guo-Zheng Ding, Min Yang

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Recently, the use of the pharmacological agents strontium ranelate (SR), parathyroid hormone (1-34, PTH) and zoledronic acid (ZA) has come to prominence for the treatment of osteoporosis due to their ability to prevent bone loss in osteoporotic patients. Although much emphasis has been placed on using pharmacological agents for the prevention of disease, much less attention has been placed on which one is more effective. There is still no direct comparative study on these three drugs. The aim of the present study was to investigate the effect of SR, PTH, ZA on preventing ovariectomy-induced osteoporosis in rats. After bilateral ovariectomy the rats randomly received vehicle, SR (500 mg/kg body weight/day, orally), PTH (20 μg/kg/day, subcutaneously) or a single injection of ZA (0.1 mg/kg, i.v.) until death at 12 weeks. The distal femurs were harvested for evaluation of bone metabolism. The rats treated with ZA demonstrated the highest levels of new bone formation as assessed by microcomputed tomography (CT), biomechanical strength, histological analysis and bone metabolism. Furthermore, PTH and SR showed a stronger effect on improving trabecular bone mass at 12 weeks. The results from the present study demonstrate that systemic administration of PTH, SR and ZA could prevent bone loss, while a single dose of ZA has a better effect on preventing ovariectomy-induced osteoporosis than either PTH or SR.
Literatur
1.
Zurück zum Zitat Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA (2002) Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2:121–128 CrossRef Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA (2002) Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2:121–128 CrossRef
2.
Zurück zum Zitat Riggs BL, Melton L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5):S505–S511 CrossRef Riggs BL, Melton L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5):S505–S511 CrossRef
4.
Zurück zum Zitat Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–1514 CrossRefPubMed Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–1514 CrossRefPubMed
5.
Zurück zum Zitat Cooper C, Campion G, Melton L III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2(6):285–289 CrossRefPubMed Cooper C, Campion G, Melton L III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2(6):285–289 CrossRefPubMed
6.
7.
Zurück zum Zitat Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475 CrossRefPubMed Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475 CrossRefPubMed
12.
Zurück zum Zitat Glatt M, Pataki A, Evans GP, Hornby SB, Green JR (2004) Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15(9):707–715 CrossRefPubMed Glatt M, Pataki A, Evans GP, Hornby SB, Green JR (2004) Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15(9):707–715 CrossRefPubMed
13.
Zurück zum Zitat Wise L, Waldman S, Kasra M, Cheung R, Binnington A, Kandel R, White L, Grynpas M (2005) Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 77(6):367–375 CrossRefPubMed Wise L, Waldman S, Kasra M, Cheung R, Binnington A, Kandel R, White L, Grynpas M (2005) Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 77(6):367–375 CrossRefPubMed
16.
Zurück zum Zitat Chao M, Hua Q, Yingfeng Z, Guang W, Shufeng S, Yuzhen D, Wei W, Haifeng T (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29(6):1381–1384 PubMedPubMedCentral Chao M, Hua Q, Yingfeng Z, Guang W, Shufeng S, Yuzhen D, Wei W, Haifeng T (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29(6):1381–1384 PubMedPubMedCentral
21.
Zurück zum Zitat Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428 CrossRefPubMed Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428 CrossRefPubMed
22.
Zurück zum Zitat Habermann B, Kafchitsas K, Olender G, Augat P, Kurth A (2010) Strontium ranelate enhances callus strength more than PTH 1‑34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86(1):82–89 CrossRefPubMed Habermann B, Kafchitsas K, Olender G, Augat P, Kurth A (2010) Strontium ranelate enhances callus strength more than PTH 1‑34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86(1):82–89 CrossRefPubMed
24.
Zurück zum Zitat Iwamoto J, Seki A, Sato Y, Matsumoto H (2012) Vitamin K(2) improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int 90(1):50–59 CrossRefPubMed Iwamoto J, Seki A, Sato Y, Matsumoto H (2012) Vitamin K(2) improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int 90(1):50–59 CrossRefPubMed
26.
Zurück zum Zitat Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638 CrossRefPubMed Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638 CrossRefPubMed
28.
Zurück zum Zitat Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42(1):90–97 CrossRefPubMed Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42(1):90–97 CrossRefPubMed
29.
Zurück zum Zitat Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2007) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18(3):351–362 CrossRefPubMed Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2007) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18(3):351–362 CrossRefPubMed
30.
Zurück zum Zitat Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1‑34). J Bone Joint Surg Am 87(4):731–741 PubMed Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1‑34). J Bone Joint Surg Am 87(4):731–741 PubMed
31.
Zurück zum Zitat Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28(3):237–250 CrossRefPubMed Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28(3):237–250 CrossRefPubMed
32.
Zurück zum Zitat Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15(1):51–58 CrossRefPubMed Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15(1):51–58 CrossRefPubMed
33.
Zurück zum Zitat Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23(4):544 CrossRefPubMed Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23(4):544 CrossRefPubMed
34.
Zurück zum Zitat Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18(7):1300 CrossRefPubMed Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18(7):1300 CrossRefPubMed
35.
Zurück zum Zitat Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978 CrossRefPubMed Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978 CrossRefPubMed
36.
Zurück zum Zitat Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J (2009) Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 32(7):1193–1198 CrossRefPubMed Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J (2009) Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 32(7):1193–1198 CrossRefPubMed
38.
Zurück zum Zitat Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822 CrossRefPubMed Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822 CrossRefPubMed
39.
Zurück zum Zitat Reginster JY, Seeman E, Vernejoul MCD, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822 CrossRefPubMed Reginster JY, Seeman E, Vernejoul MCD, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822 CrossRefPubMed
40.
Zurück zum Zitat Saffar JL (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468 CrossRef Saffar JL (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468 CrossRef
45.
Zurück zum Zitat Komrakova M, Hoffmann DB, Nuehnen V, Stueber H, Wassmann M, Wicke M, Tezval M, Stuermer KM, Sehmisch S (2016) The effect of vibration treatments combined with teriparatide or strontium ranelate on bone healing and muscle in ovariectomized rats. Calcif Tissue Int 99(4):1–15 CrossRef Komrakova M, Hoffmann DB, Nuehnen V, Stueber H, Wassmann M, Wicke M, Tezval M, Stuermer KM, Sehmisch S (2016) The effect of vibration treatments combined with teriparatide or strontium ranelate on bone healing and muscle in ovariectomized rats. Calcif Tissue Int 99(4):1–15 CrossRef
Metadaten
Titel
Prevention of ovariectomy-induced osteoporosis in rats
Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate
verfasst von
Zhou-Shan Tao
Wan-Shu Zhou
Xing-Jing Wu
Xin Zhang
Lin Wang
Jia-Bing Xie
Zhu-Jun Xu
Guo-Zheng Ding
Min Yang
Publikationsdatum
23.02.2018
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2019
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-018-1376-x